+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030- Product Image
Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079690
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Targeted therapy drugs have redefined melanoma treatment by enabling precision-driven regimens and improved patient outcomes. The evolving market for melanoma targeted therapy is marked by continuous innovation, shifting policy dynamics, and intensifying competitive strategies, positioning it at the forefront of oncology advances for decision-makers seeking growth and impact.

Market Snapshot: Melanoma Targeted Therapy Market

According to recent analysis, the global melanoma targeted therapy market is demonstrating strong expansion, propelled by adoption of mechanism-based therapeutics and breakthroughs in immuno-oncology. The market’s key drivers include advances in molecular profiling, the integration of combination regimens, and increasing prioritization of tailored treatment protocols. Regional dynamics remain highly influential, with innovation uptake varying across developed and emerging economies, while ongoing regulatory adjustments present both opportunities and complexities for stakeholders.

Scope & Segmentation of the Melanoma Targeted Therapy Market

This report delivers an in-depth breakdown of the melanoma targeted therapy landscape, structured around core modalities, administration methods, lines of therapy, and market channel distinctions. The full scope includes regional analysis and profiles of influential industry leaders.

  • Mechanism Of Action: BRAF inhibitors, CTLA-4 inhibitors, MEK inhibitors, and PD-1 inhibitors (including agents such as dabrafenib, encorafenib, vemurafenib, ipilimumab, binimetinib, cobimetinib, trametinib, nivolumab, and pembrolizumab)
  • Route Of Administration: Intravenous and oral formulations to support hospital-based and outpatient management
  • Treatment Line: First-line, second-line, and subsequent regimen positioning with an emphasis on sequence optimization and resistance management
  • Distribution Channel: Hospital pharmacy, online pharmacy, and retail pharmacy models
  • End User: Hospitals, oncology centers, and ambulatory surgical centers, each with unique treatment delivery dynamics
  • Key Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (key countries include United Kingdom, Germany, France, Russia, among others), and Asia-Pacific (including China, India, Japan, Australia, and Southeast Asian nations)
  • Leading Companies: Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Genentech, Inc., and Array BioPharma LLC

Key Takeaways for Senior Decision-Makers

  • The primary keyword, melanoma targeted therapy, remains central to market advancements due to the persistent integration of targeted and immunotherapeutic approaches.
  • Combination regimens, especially those uniting BRAF and MEK inhibitors, are setting new therapeutic standards, driven by mechanistic synergies that offer robust progression-free survival outcomes.
  • Emergent biomarkers and liquid biopsy technologies are refining patient stratification, allowing for more responsive and personalized treatment adjustment.
  • Shift toward digital pharmacy and direct-to-patient delivery reflects an industry-wide focus on accessibility, adherence, and cost-effectiveness.
  • Strategic partnerships across biotechnology, diagnostics, and manufacturing sectors are spurring the next generation of resistance-targeted therapies and driving portfolio diversification.
  • Regional market adoption is shaped by healthcare infrastructure, with developed economies leading protocol innovation and emerging markets advancing through access programs and biosimilar introductions.

Tariff Impact: Navigating US 2025 Policy Changes

The 2025 US tariff policy changes have introduced new complexities across the targeted melanoma drugs supply chain. Manufacturers are recalibrating sourcing strategies and operational footprints in response to shifting import duty structures, leading to increased emphasis on process optimization, strategic stockpiling, and select relocation to tariff-exempt areas. Payers and health systems are engaged in active negotiation to maintain therapy access and affordability. These dynamics highlight the industry’s need for operational agility and cross-stakeholder collaboration.

Methodology & Data Sources

The analysis integrates comprehensive secondary research—spanning peer-reviewed journals, regulatory documents, and proprietary intelligence platforms—with primary insights from interviews with industry leaders and payers. Quantitative data is cross-validated with qualitative input to ensure actionable, real-world perspectives on core themes such as reimbursement, adoption, and innovation. The research leverages segmentation analysis and regional market modeling to deliver a robust, decision-ready view.

Why This Report Matters

  • Enables senior executives to benchmark their organization’s portfolio against the latest targeted therapy strategies and identify emerging competitive threats.
  • Equips market access and commercial teams with actionable insights to optimize go-to-market strategy tailored to unique regional and segment-specific challenges.
  • Supports proactive planning for policy-driven impacts—including tariffs—through scenario analysis and validated adaptation models.

Conclusion

Targeted therapy continues to transform the melanoma treatment landscape with sustained innovation, adaptive strategies, and proven patient impact. This report offers senior decision-makers the critical intelligence needed to navigate complexity and capture opportunity in a competitive oncology market.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Therapy Drugs for Melanoma Market, by Mechanism Of Action
8.1. Introduction
8.2. BRAF Inhibitors
8.2.1. Dabrafenib
8.2.2. Encorafenib
8.2.3. Vemurafenib
8.3. CTLA-4 Inhibitors
8.3.1. Ipilimumab
8.4. MEK Inhibitors
8.4.1. Binimetinib
8.4.2. Cobimetinib
8.4.3. Trametinib
8.5. PD-1 Inhibitors
8.5.1. Nivolumab
8.5.2. Pembrolizumab
9. Targeted Therapy Drugs for Melanoma Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Targeted Therapy Drugs for Melanoma Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Targeted Therapy Drugs for Melanoma Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Targeted Therapy Drugs for Melanoma Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Center
12.3. Hospital
12.4. Oncology Center
13. Americas Targeted Therapy Drugs for Melanoma Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Targeted Therapy Drugs for Melanoma Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Targeted Therapy Drugs for Melanoma Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. F. Hoffmann-La Roche Ltd
16.3.3. Pfizer Inc.
16.3.4. Genentech, Inc.
16.3.5. Array BioPharma LLC
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TARGETED THERAPY DRUGS FOR MELANOMA MARKET MULTI-CURRENCY
FIGURE 2. TARGETED THERAPY DRUGS FOR MELANOMA MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED THERAPY DRUGS FOR MELANOMA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TARGETED THERAPY DRUGS FOR MELANOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TARGETED THERAPY DRUGS FOR MELANOMA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED THERAPY DRUGS FOR MELANOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 61. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 66. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. FRANCE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 148. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. ITALY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SPAIN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 187. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. DENMARK TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 205. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 211. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. QATAR TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 214. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. FINLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 241. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. EGYPT TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 250. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. TURKEY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 268. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. NORWAY TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 279. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 283. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. POLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Targeted Therapy Drugs for Melanoma market report include:
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Genentech, Inc.
  • Array BioPharma LLC

Related Topics

Related Reports

Melanoma Drug Market by Distribution Channel, Route Of Administration, Line Of Therapy, Therapy Type, Mechanism Of Action - Global Forecast to 2030 - Product Image

Melanoma Drug Market by Distribution Channel, Route Of Administration, Line Of Therapy, Therapy Type, Mechanism Of Action - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Untreated Metastatic Or Unresectable Melanoma- Pipeline Insight, 2025 - Product Image

Untreated Metastatic Or Unresectable Melanoma- Pipeline Insight, 2025

  • Drug Pipelines
  • 80 Pages
  • Global
From
Advanced Melanoma - Pipeline Insight, 2025 - Product Image

Advanced Melanoma - Pipeline Insight, 2025

  • Drug Pipelines
  • 180 Pages
  • Global
From
Skin Cancer Drugs - Global Strategic Business Report - Product Image

Skin Cancer Drugs - Global Strategic Business Report

  • Report
  • 483 Pages
  • Global
From
Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030 - Product Image

Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.